



The Janssen Pharmaceutical Companies of Johnson & Johnson

Christian Rodseth
Managing Director Janssen Greece Poland Romania

5 Oct 2022, AMCHAM HEATHWORLD CONFERENCE

Peter Sas
Spring in the Forest

WE deliver truly remarkable solutions that provide value to patients, healthcare professionals and healthcare systems.

WE advocate for sustainable healthcare systems that value innovation and provide access for therapies to patients around the world.

WE are Janssen



Janssen EMEA is invested in the EMEA region

30+

Countries

14,000+


Employees

7

R&D sites

€1.5Billion

Annual R&D investments



Pharmaceutical Innovation drives & enhances economic growth

- Improves and extends quality of life of patients
- Upgrades Health care system through clinical trials
- Brings new technological know how in the economy
- Creates new jobs
- Strengthens society



The Health care environment requires increased investment to meet patient needs

Public Health care spend in Greece represents **5.9%** of GDP, compared to **8.8%** on average in EU



The Pharmaceutical environment hampered by under investment

Public pharmaceutical budget remains unchanged since 2014

Public pharmaceutical budget is **24%** below the EU average per capita

Absence of a long-term strategy to rationalize prescribing and expenditure

7 out of 10 products paid by pharmaceutical companies

Unsustainable total paybacks for pharma industry



Investing in patient health means ...

- Increasing the public contribution to pharmaceutical expenditure
- Accelerating digital health transformation
- Implementing structural reforms to generate efficiencies in patient care



Attracts international investments in health & Greece

We are committed to Collaboration that:

benefits the
sustainability of the
Health Care System
and serves all **patients**
and **society** at large.



**We are creating a future where,
disease is a thing of a past.**

Είμαστε η

Janssen

PHARMACEUTICAL COMPANIES OF

Johnson & Johnson

